Erasca, a company focused on therapies for RAS-driven cancers, received FDA clearance for its IND applications.
3 reports, 1 independent
Updated Sep 4
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Erasca, a company focused on therapies for RAS-driven cancers, received FDA clearance for its IND applications.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Erasca (United States)
company in San Diego, United States
Nothing else this week.
- FDA
Related events
- Fate Therapeutics, based in San Diego, is seeking support for an accelerated regulatory pathway from the FDA.
- Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.
- Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Michael Davis takes a permanent leadership role at the FDA's Center for Drug Evaluation and Research following senior selections announced by the Department of Health & Human Services.
Coverage
Newest first; wire copies grouped- GlobeNewswireErasca Reports Second Quarter 2025 Business Updates and Financial Results Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 m